• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Glenmark Pharma gets ANDA approval for Tacrolimus Capsules

expresspharmaNovember 12, 2020

Tag: ANDA , Glenmark , Astellas , Tacrolimus Capsules

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (US FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg, the generic version of Prograf Capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharm US, Inc.

According to IQVIA, sales data for the 12 month period ending September 2020, the Prograf Capsules, 0.5 mg, 1 mg and 5 mg market2 achieved annual sales of approximately $286.8 million.

Glenmark’s current portfolio consists of 166 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

Previous:Sputnik V vaccine shows 92 per cent efficacy in ongoing phase III trials in Russia

Next:SCHOTT Glass India inaugurates new glass melting tank at Gujarat facility

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Glenmark Pharma gets ANDA approval for Tacrolimus Capsules | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

LGJ-18 Standard Type Experimental Freeze Dryer

LGJ-18 Standard Type Experimental Freeze Dryer
Ergot secale cornutum ErgotErgota spurred rye extract ergosterol ergosterin Ergosterol Standard Hydr

Ergot secale cornutum ErgotErgota spurred rye extract ergosterol ergosterin Ergosterol Standard Hydr
Gauze Bandage

Gauze Bandage
Elastic plain weave bandage

Elastic plain weave bandage
The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING

The LUMiFrac CAT TECHNOLOGY: THE NEW STANDARD IN ADHESION TESTING
Graphite for Expandable Polystyrene (EPS)

Graphite for Expandable Polystyrene (EPS)
Belamcanda Extract

Belamcanda Extract
High elastic bandage

High elastic bandage
toc standard method

toc standard method
YSF standard type frequency conversion speed regulating double layer glass reaction kettle

YSF standard type frequency conversion speed regulating double layer glass reaction kettle

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service